Related Experiment Video
Updated: Apr 11, 2026
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Real-World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a
Katelyn Oranges1, Kelly A Duffy1, Sara McDonough1
1Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Insights
Blinatumomab is effective for pediatric B-ALL but real-world use is limited. This report details overcoming access barriers for hospital-dispensed blinatumomab, improving patient access to this standard of care therapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Pharmacology
Background:
- Blinatumomab is a highly effective therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL).
- It has recently been established as a standard of care treatment for B-ALL.
- Limited real-world data exists on blinatumomab administration outside of clinical trials.
Purpose of the Study:
- To describe the institutional experience with blinatumomab as standard of care therapy.
- To identify and address challenges in real-world blinatumomab administration.
- To report on the development of a hospital-dispensed model to improve patient access.
Main Methods:
- Retrospective review of institutional experience with blinatumomab.
- Analysis of challenges related to patient access, particularly for those lacking home health coverage.
- Description of the implementation process for a hospital-dispensed medication system.
Main Results:
- Blinatumomab administration presented initial access challenges for patients without home health coverage.
- Implementation of a hospital-dispensed blinatumomab process was successful.
- This process significantly reduced barriers to accessing blinatumomab therapy.
Conclusions:
- Real-world implementation of blinatumomab requires addressing logistical and access barriers.
- A hospital-dispensed model can effectively overcome challenges in blinatumomab administration.
- Improving access to blinatumomab ensures patients receive this vital standard of care therapy for pediatric B-ALL.
Abstract:
Blinatumomab has been shown to be highly effective for patients with pediatric B-ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real-world administration. In this brief report, we describe our institutional experience administering blinatumomab during the first year as standard of care therapy, including initial challenges in providing access to patients without home health coverage. We describe our process for developing and implementing a process for hospital-dispensed blinatumomab, which reduced access barriers for patients.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:30Specialized Care Centers and Settings-II
Rural health centers are specialized care facilities in remote locations with very few medical personnel. The primary care providers who run the centers are mostly Registered Nurse Practitioners. Here, emergency treatment is provided to critically ill or injured patients before they are transferred to the closest hospital. Fortunately, due to advancement in technology, many rural healthcare facilities and professionals have easy access to diagnostic and treatment...
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...